{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:38:24Z","timestamp":1793817504730,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cisplatin based chemotherapy cures over 80% of metastatic testicular germ cell tumours (TGCT). In contrast, almost all other solid cancers in adults are incurable once they have spread beyond the primary site. Cell lines derived from TGCTs are hypersensitive to cisplatin reflecting the clinical response. Earlier findings suggested that a reduced repair capacity might contribute to the cisplatin hypersensitivity of testis tumour cells (TTC), but the critical DNA damage has not been defined. This study was aimed at investigating the formation and repair of intrastrand and interstrand crosslinks (ICLs) induced by cisplatin in TTC and their contribution to TTC hypersensitivity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We observed that repair of intrastrand crosslinks is similar in cisplatin sensitive TTC and resistant bladder cancer cells, whereas repair of ICLs was significantly reduced in TTC. \u03b3H2AX formation, which serves as a marker of DNA breaks formed in response to ICLs, persisted in cisplatin-treated TTC and correlated with sustained phosphorylation of Chk2 and enhanced PARP-1 cleavage. Expression of the nucleotide excision repair factor ERCC1-XPF, which is implicated in the processing of ICLs, is reduced in TTC. To analyse the causal role of ERCC1-XPF for ICL repair and cisplatin sensitivity, we over-expressed ERCC1-XPF in TTC by transient transfection. Over-expression increased ICL repair and rendered TTC more resistant to cisplatin, which suggests that ERCC1-XPF is rate-limiting for repair of ICLs resulting in the observed cisplatin hypersensitivity of TTC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our data indicate for the first time that the exceptional sensitivity of TTC and, therefore, very likely the curability of TGCT rests on their limited ICL repair due to low level of expression of ERCC1-XPF.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1476-4598-9-248","type":"journal-article","created":{"date-parts":[[2010,9,16]],"date-time":"2010-09-16T18:15:03Z","timestamp":1284660903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression"],"prefix":"10.1186","volume":"9","author":[{"given":"Svetlana","family":"Usanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pi\u00e9e-Staffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Sied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Thomale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kaina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"K\u00f6berle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,16]]},"reference":[{"key":"763_CR1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(06)68305-0","volume":"367","author":"A Horwich","year":"2006","unstructured":"Horwich A, Shipley J, Huddart R: Testicular germ-cell cancer. Lancet. 2006, 367: 754-765. 10.1016\/S0140-6736(06)68305-0","journal-title":"Lancet"},{"key":"763_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007, 33: 9-23. 10.1016\/j.ctrv.2006.09.006","journal-title":"Cancer Treat Rev"},{"key":"763_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ijc.2910530228","volume":"53","author":"JRW Masters","year":"1993","unstructured":"Masters JRW, Osborne EJ, Walker MC, Parris CN: Hypersensitivity of human testis-tumour cell lines to chemotherapeutic drugs. Int J Cancer. 1993, 53: 340-346. 10.1002\/ijc.2910530228","journal-title":"Int J Cancer"},{"key":"763_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc1120","volume":"3","author":"JR Masters","year":"2003","unstructured":"Masters JR, K\u00f6berle B: Curing metastatic cancer: lessons from testicular germ-cell tumours. Nature Rev Cancer. 2003, 3: 517-525. 10.1038\/nrc1120.","journal-title":"Nature Rev Cancer"},{"key":"763_CR5","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1021\/bi00361a026","volume":"25","author":"A Eastman","year":"1986","unstructured":"Eastman A: Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry. 1986, 25: 3912-3915. 10.1021\/bi00361a026","journal-title":"Biochemistry"},{"key":"763_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(01)00454-5","volume":"2","author":"PJ McHugh","year":"2001","unstructured":"McHugh PJ, Spanswick VJ, Hartley JA: Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. The Lancet Oncology. 2001, 2: 483-490. 10.1016\/S1470-2045(01)00454-5","journal-title":"The Lancet Oncology"},{"key":"763_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ijc.20134","volume":"110","author":"C Welsh","year":"2004","unstructured":"Welsh C, Day R, McGurk C, Masters JR, Wood RD, Koberle B: Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer. 2004, 110: 352-361. 10.1002\/ijc.20134","journal-title":"Int J Cancer"},{"key":"763_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G","volume":"70","author":"B K\u00f6berle","year":"1997","unstructured":"K\u00f6berle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR: DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer. 1997, 70: 551-555. 10.1002\/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G","journal-title":"Int J Cancer"},{"key":"763_CR9","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkl051","volume":"34","author":"B Liedert","year":"2006","unstructured":"Liedert B, Pluim D, Schellens J, Thomale J: Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res. 2006, 34: e47- 10.1093\/nar\/gkl051","journal-title":"Nucleic Acids Res"},{"key":"763_CR10","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1093\/nar\/gkf479","volume":"30","author":"IU De Silva","year":"2002","unstructured":"De Silva IU, McHugh PJ, Clingen PH, Hartley JA: Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res. 2002, 30: 3848-3856. 10.1093\/nar\/gkf479","journal-title":"Nucleic Acids Res"},{"key":"763_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/0027-5107(82)90281-0","volume":"95","author":"R Wood","year":"1982","unstructured":"Wood R, Burki HJ: Repair capability and the cellular age response for killing and mutation induction after UV. Mutat Res. 1982, 95: 505-514.","journal-title":"Mutat Res"},{"key":"763_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bcp.2008.03.025","volume":"76","author":"PH Clingen","year":"2008","unstructured":"Clingen PH, Wu JY, Miller J, Mistry N, Chin F, Wynne P, Prise KM, Hartley JA: Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol. 2008, 76: 19-27. 10.1016\/j.bcp.2008.03.025","journal-title":"Biochem Pharmacol"},{"key":"763_CR13","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"ZH Siddik","year":"2003","unstructured":"Siddik ZH: Cisplatin: mode of action and molecular basis of resistance. Oncogene. 2003, 22: 7265-7279. 10.1038\/sj.onc.1206933","journal-title":"Oncogene"},{"key":"763_CR14","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.1074\/jbc.M707568200","volume":"283","author":"N Pabla","year":"2008","unstructured":"Pabla N, Huang S, Mi Q-S, Daniel R, Dong Z: ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem. 2008, 283: 6572-6583. 10.1074\/jbc.M707568200","journal-title":"J Biol Chem"},{"key":"763_CR15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.molcel.2009.08.014","volume":"35","author":"M Ben-Yehoyada","year":"2009","unstructured":"Ben-Yehoyada M, Wang LC, Kozekov ID, Rizzo CJ, Gottesman ME, Gautier J: Checkpoint signaling from a single DNA interstrand crosslink. Mol Cell. 2009, 35: 704-715. 10.1016\/j.molcel.2009.08.014","journal-title":"Mol Cell"},{"key":"763_CR16","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.1128\/MCB.24.13.5776-5787.2004","volume":"24","author":"LJ Niedernhofer","year":"2004","unstructured":"Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NG, Beverloo HB, Hoeijmakers JH, Kanaar R: The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol. 2004, 24: 5776-5787. 10.1128\/MCB.24.13.5776-5787.2004","journal-title":"Mol Cell Biol"},{"key":"763_CR17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0092-8674(00)80155-5","volume":"86","author":"AM Sijbers","year":"1996","unstructured":"Sijbers AM, de Laat WL, Ariza RR, Biggerstaff M, Wei Y-F, Moggs JG, Carter KC, Shell BK, Evans E, de Jong MC: Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell. 1996, 86: 811-822. 10.1016\/S0092-8674(00)80155-5","journal-title":"Cell"},{"key":"763_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/carcin\/19.1.55","volume":"19","author":"T Yagi","year":"1998","unstructured":"Yagi T, Matsumura Y, Sato M, Nishigori C, Mori T, Sijbers AM, Takebe H: Complete restoration of normal DNA repair characteristics in group F xeroderma pigmentosum cells by over-expression of transfected XPF cDNA. Carcinogenesis. 1998, 19: 55-60. 10.1093\/carcin\/19.1.55","journal-title":"Carcinogenesis"},{"key":"763_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.molmed.2006.07.007","volume":"12","author":"WP Roos","year":"2006","unstructured":"Roos WP, Kaina B: DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006, 12: 440-450. 10.1016\/j.molmed.2006.07.007","journal-title":"Trends Mol Med"},{"key":"763_CR20","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/mc.20418","volume":"47","author":"B K\u00f6berle","year":"2008","unstructured":"K\u00f6berle B, Roginskaya V, Zima KS, Masters JR, Wood RD: Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation. Mol Carcinog. 2008, 47: 580-586. 10.1002\/mc.20418","journal-title":"Mol Carcinog"},{"key":"763_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0960-9822(99)80118-3","volume":"9","author":"B K\u00f6berle","year":"1999","unstructured":"K\u00f6berle B, Masters JR, Hartley JA, Wood RD: Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol. 1999, 9: 273-276. 10.1016\/S0960-9822(99)80118-3","journal-title":"Curr Biol"},{"key":"763_CR22","doi-asserted-by":"publisher","first-page":"26632","DOI":"10.1074\/jbc.C000337200","volume":"275","author":"I Kuraoka","year":"2000","unstructured":"Kuraoka I, Kobertz WR, Ariza RR, Biggerstaff M, Essigmann JM, Wood RD: Repair of an interstrand DNA crosslink initiated by ERCC1-XPF repair\/recombination nuclease. J Biol Chem. 2000, 275: 26632-26636. 10.1074\/jbc.C000337200","journal-title":"J Biol Chem"},{"key":"763_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.dnarep.2005.12.001","volume":"5","author":"B K\u00f6berle","year":"2006","unstructured":"K\u00f6berle B, Roginskaya V, Wood RD: XPA protein as a limiting factor for nucleotide excision repair and UV sensitivity in human cells. DNA Repair. 2006, 5: 641-648. 10.1016\/j.dnarep.2005.12.001","journal-title":"DNA Repair"},{"key":"763_CR24","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1128\/MCB.23.16.5755-5767.2003","volume":"23","author":"S Rademakers","year":"2003","unstructured":"Rademakers S, Volker M, Hoogstraten D, Nigg AL, Mone MJ, Van Zeeland AA, Hoeijmakers JH, Houtsmuller AB, Vermeulen W: Xeroderma pigmentosum group A protein loads as a separate factor onto DNA lesions. Mol Cell Biol. 2003, 23: 5755-5767. 10.1128\/MCB.23.16.5755-5767.2003","journal-title":"Mol Cell Biol"},{"key":"763_CR25","doi-asserted-by":"publisher","first-page":"15933","DOI":"10.1073\/pnas.0403664101","volume":"101","author":"MJ Mone","year":"2004","unstructured":"Mone MJ, Bernas T, Dinant C, Goedvree FA, Manders EM, Volker M, Houtsmuller AB, Hoeijmakers JH, Vermeulen W, van Driel R: In vivo dynamics of chromatin-associated complex formation in mammalian nucleotide excision repair. Proc Natl Acad Sci USA. 2004, 101: 15933-15937. 10.1073\/pnas.0403664101","journal-title":"Proc Natl Acad Sci USA"},{"key":"763_CR26","first-page":"645","volume":"20","author":"Q Li","year":"2000","unstructured":"Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E: Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res. 2000, 20: 645-652.","journal-title":"Anticancer Res"},{"key":"763_CR27","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0006-2952(00)00441-X","volume":"60","author":"KV Ferry","year":"2000","unstructured":"Ferry KV, Hamilton TC, Johnson SW: Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol. 2000, 60: 1305-1313. 10.1016\/S0006-2952(00)00441-X","journal-title":"Biochem Pharmacol"},{"key":"763_CR28","first-page":"2286","volume":"8","author":"RV Lord","year":"2002","unstructured":"Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002, 8: 2286-2291.","journal-title":"Clin Cancer Res"},{"key":"763_CR29","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1200\/JCO.2001.19.23.4298","volume":"19","author":"Y Shirota","year":"2001","unstructured":"Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001, 19: 4298-4304.","journal-title":"J Clin Oncol"},{"key":"763_CR30","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1056\/NEJMoa060570","volume":"355","author":"KA Olaussen","year":"2006","unstructured":"Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006, 355: 983-991. 10.1056\/NEJMoa060570","journal-title":"N Engl J Med"},{"key":"763_CR31","volume-title":"BBA Reviews on Cancer","author":"B K\u00f6berle","year":"2010","unstructured":"K\u00f6berle B, Tomicic M, Usanova S, Kaina B: Cisplatin resistance: preclinical findings and clinical implications. BBA Reviews on Cancer. 2010"},{"key":"763_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.molmed.2005.09.004","volume":"11","author":"S Madhusudan","year":"2005","unstructured":"Madhusudan S, Hickson ID: DNA repair inhibition: a selective tumour targeting strategy. Trends Mol Med. 2005, 11: 503-511. 10.1016\/j.molmed.2005.09.004","journal-title":"Trends Mol Med"},{"key":"763_CR33","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/j.ejca.2007.05.003","volume":"43","author":"G Damia","year":"2007","unstructured":"Damia G, D'Incalci M: Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer. 2007, 43: 1791-1801. 10.1016\/j.ejca.2007.05.003","journal-title":"Eur J Cancer"},{"key":"763_CR34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.tips.2006.04.007","volume":"27","author":"J Ding","year":"2006","unstructured":"Ding J, Miao Z-H, Meng L-H, Geng M-Y: Emerging cancer therapeutic opportunities target DNA repair systems. Trends Pharmacol Scl. 2006, 27: 338-344. 10.1016\/j.tips.2006.04.007.","journal-title":"Trends Pharmacol Scl"},{"key":"763_CR35","unstructured":"Kaina B, Margison G, Christmann M: Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cellular and Molecular Life Sciences."},{"key":"763_CR36","first-page":"4529","volume":"59","author":"H Jiang","year":"1999","unstructured":"Jiang H, Yang LY: Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: Association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins. Cancer Res. 1999, 59: 4529-4534.","journal-title":"Cancer Res"},{"key":"763_CR37","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/nar\/29.4.872","volume":"29","author":"PH Gaillard","year":"2001","unstructured":"Gaillard PH, Wood RD: Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair. Nucleic Acids Res. 2001, 29: 872-879. 10.1093\/nar\/29.4.872","journal-title":"Nucleic Acids Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-9-248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T12:04:46Z","timestamp":1630497886000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-9-248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,16]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-9-248","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,16]]},"assertion":[{"value":"11 May 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"248"}}